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Abstract
Surgical resection is the only curative treatment for biliary tract cancer (BTC); however, the recurrence rate remains
high even after curative resection. There are limited data regarding the effectiveness of surgical resection for
recurrent BTC. We report the favorable survival outcome of a patient who underwent a
hepatopancreatoduodenectomy for local recurrence of cholangiocarcinoma after excision of a type IV-A congenital
choledochal cyst. The patient, a 25-year-old woman, had undergone excision of a type IV-A congenital choledochal
cyst with hepaticojejunostomy. The resected specimen revealed an early cholangiocarcinoma. The local recurrence
at the site of anastomosis was detected 4 years and 4 months after surgery. We performed a left trisectionectomy
with caudate lobectomy combined with hepatic artery and portal vein resections and a pancreaticoduodenectomy.
Histological examination revealed a moderately differentiated adenocarcinoma, and the final diagnosis was recurrence
of cholangiocarcinoma. There are a few reports of extensive resection for recurrence of BTC; however, aggressive
surgery is possible and may offer favorable survival in selected patients.
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Background
Surgical resection is the only curative treatment for bil-
iary tract cancer (BTC), including cholangiocarcinoma
[1] and gallbladder carcinoma [2]. The 5-year survival
rate is unsatisfactory even after curative resection:
33.1 % in cholangiocarcinoma and 41.6 % in gallbladder
carcinoma [3]. The recurrence rate remains high and is
reported to range from 46 to 71 % [4–6]. Most patients
with recurrence undergo systemic chemotherapy [7].
However, the survival benefit is insufficient; Valle et al
[7] reported in their trial that the median overall survival
was only 11.7 months and no patients survived for more
than 3 years. Recently, the effectiveness of surgical treat-
ment for recurrence of BTC has been reported [4, 8, 9].
To our knowledge, few cases of recurrent BTC treated
by hepatopancreatoduodenectomy (HPD) have been
reported. Here, we report the favorable survival outcome
of a patient who underwent an HPD combined with
hepatic artery and portal vein (PV) resections for chol-
angiocarcinoma recurrence arising after a surgery for a
type IV-A congenital choledochal cyst.
Case presentation
A 25-year-old woman who was diagnosed with recur-
rence of cholangiocarcinoma after excision of a type IV-
A congenital choledochal cyst was referred to our
hospital for further evaluation and treatment. The pa-
tient had undergone excision of a congenital choledochal
cyst with Roux-en-Y hepaticojejunostomy reconstruction
5 years prior. The pathological examination of the
resected specimen revealed a well-differentiated tubular
adenocarcinoma invading the fibromuscular layer in the
cyst wall. Four years and 4 months after the excision, ab-
dominal computed tomography (CT) revealed a mass at
the hepatic hilum with narrowing of the hepaticojejunal
anastomosis and duodenum. Percutaneous transhepatic
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biliary drainage was performed, but the cytology specimen
was negative for malignant cells. Furthermore, although
the patient underwent gastrojejunostomy because of duo-
denal stenosis, a specimen could not be taken from the
mass; therefore, she was diagnosed with a recurrence of
cholangiocarcinoma based on the laparotomy findings.
The patient underwent a metallic stent placement at the
narrow site of the anastomosis and systemic chemother-
apy with gemcitabine. However, because of repeated bouts
of cholangitis, the patient was transferred to our hospital
for possible surgery.
When the patient was transferred, she presented with
no symptoms. Liver function tests revealed the following
slight abnormalities: total bilirubin, 0.7 mg/dl; aspartate
aminotransferase, 23 IU/l; alanine aminotransferase,
16 IU/l; γ-glutamyl transpeptidase, 64 IU/l; and alkaline
phosphatase, 225 IU/l. The serum carcinoembryonic
antigen level was 1.4 IU/l, and the carbohydrate antigen
19-9 level was elevated to 255 IU/l. The plasma clear-
ance rate of indocyanine green was 0.213.
CT revealed a mass over the pancreatic head from the
hepatic hilum with an unclear and irregular border in-
vading the duodenum and pancreatic head (Fig. 1). The
mass invaded from the main PV to the bifurcation of the
right anterior and posterior PV. The main PV was se-
verely strictured (Fig. 2a). The common hepatic artery,
gastroduodenal artery, and right and left hepatic arteries
were also involved by the mass.
Angiography revealed that the right posterior hepatic
artery was invaded and disrupted at the hepatic hilum.
Furthermore, a collateral artery from the right anterior
hepatic artery to the right posterior hepatic artery was
observed (Fig. 3).
Cholangiography revealed cystic dilation of the left
hepatic duct, right anterior hepatic duct, and right hep-
atic duct. There were intrahepatic calculi in the right
posterior hepatic duct (Fig. 4). Bile cytology was nega-
tive. Although a histological diagnosis was unable to be
made, according to these findings, we diagnosed this
case as a recurrence of cholangiocarcinoma with inva-
sion of the duodenum, pancreatic head, right hepatic ar-
tery, and main PV (Fig. 5). A left trisectionectomy with
caudate lobectomy accompanied by right hepatic artery
and PV resections and a pancreaticoduodenectomy (PD)
were scheduled.
Although the future remnant liver function was
sufficient, we preoperatively performed transhepatic
PV stenting to reduce the flow within the collateral
vein and left and right anterior PV embolizations
(PVE) to increase liver function (Fig. 2b). Intrahepatic
calculi were not removed before the surgery because
of the high possibility of bleeding from the intrahepa-
tic duct.
The patient then underwent an extended surgery as
scheduled. Because of the infiltration of the transverse
colon mesentery, the patient also underwent a partial
colectomy. PV reconstruction was performed using a
right external iliac vein interposition grafting. Because
the patency of the right posterior hepatic artery failed to
be confirmed, arterioportal shunting (APS) was per-
formed by anastomosing the common hepatic artery to
the PV using a left radial artery interposition graft
(Fig. 6). The surgical time was 1167 min, and blood loss
was 10,799 ml.
The patient developed postoperative sepsis and a grade
B (International Study Group of Pancreatic Surgery)
pancreatic fistula. Both of these complications resolved
through conservative therapy. The flow from the sub-
phrenic artery to the remnant liver was confirmed on
postoperative day 3, whereas the arterioportal anasto-
mosis was spontaneously obstructed by postoperative
day 24. Macroscopically, the mass at the hepatic hilum
invaded the duodenum, jejunum, and pancreatic head
(Fig. 7a). Histological examination revealed a moderately
differentiated adenocarcinoma with infiltration of the
pancreatic head, jejunum, and wall of the PV (Fig. 7b).
The hepatic artery was surrounded by tumor cells. Thus,
a diagnosis of cholangiocarcinoma recurrence was made.
The patient was discharged on postoperative day 46 in
good health.
The patient received postoperative systemic chemo-
therapy with gemcitabine. Two years and 6 months after
surgery, a metastatic mass in the abdominal wall was re-
vealed, and the patient underwent resection of the mass
twice. However, a year after the last resection, the mass
Fig. 1 Computed tomography. A mass with an unclear and irregular
border (yellow arrow heads) spreads from the hepatic hilum to the
pancreatic head and invades the duodenum and the pancreatic
head. The intrahepatic bile ducts were dilated (black arrows). Ph
pancreatic head, asterisk metallic stent
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of the abdominal wall invaded the small intestine and
was judged unresectable. The patient died from the pri-
mary disease 7 years and 2 months after HPD.
Discussion
A few surgical studies for BTC recurrence have been re-
ported. According to our search of the English literature,
there are several case reports [5, 6, 10] and three retro-
spective cohort studies [4, 8, 9] pertaining to the surgical
treatment of BTC. The three studies are as follows:
Takahashi et al [4] performed surgery for recurrence in
74 (12.2 %) of the 606 patients with BTC. The surgeries
for locoregional recurrence included nine hepatectomies
with extrahepatic bile duct resections, vessel resections,
and PDs, which were challenging and technically
demanding surgeries. The survival after recurrence in
the resection group was significantly better than that
in the non-resection group (survival rate, 37 % vs.
3 % at 3 years and 14 % vs. 0.3 % at 5 years; P <
0.001). Song et al. [8] performed surgery for recur-
rence in 27 (8.5 %) of the 316 patients with BTC,
Fig. 2 Portography. a Portal vein stenosis (a red arrow) with collateral veins from the left gastric vein are shown (dotted black arrows). b After
performing a portal vein stenting and left portal vein embolization, the portal vein stenosis was resolved. LGV left gastric vein, RAPV right anterior
portal vein, RPPV right posterior portal vein, LPV left portal vein, asterisk metallic stent placed in the portal vein
Fig. 3 Angiography. The right posterior hepatic artery is disrupted at
the hepatic hilum (a red arrow), and there is a collateral artery (a
yellow arrow) from the right anterior hepatic artery to the right
posterior hepatic artery. CHA common hepatic artery, GDA
gastroduodenal artery, LHA left hepatic artery, RAHA right
posterior hepatic artery, RPHA right posterior hepatic artery
Fig. 4 Cholangiography. The cystic dilation of the left hepatic duct
(LHD), right anterior hepatic duct, and right hepatic duct are shown.
There are intrahepatic calculi in the right posterior hepatic duct
(a black arrow)
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including 7 hepatectomies, 8 PDs, and 12 other sur-
geries. The authors also reported significantly better
survival after recurrence in cases of surgical treatment
(median survival time after recurrence, 18.9 vs. 7.7 months;
P < 0.001). Noji et al. [9] performed surgery for recurrence
in 27 (18 %) of the 150 patients with gallbladder carcin-
oma and extrahepatic cholangiocarcinoma, including 18
hepatectomies (7 major and 11 non-anatomical hepatecto-
mies), 1 non-anatomical hepatectomy and inferior venous
cava/jejunum/colon/diaphragm resection, 2 PDs, and 9
other surgeries. The authors reported that survival in pa-
tients with resection was significantly better than in those
without resection (overall cumulative 5-year survival rate,
23.6 % vs. 0 %; median survival time, 21.6 vs. 9.5 months;
P < 0.01).
Thus, three studies concluded that resection for recur-
rence of BTC in selected patients (8.5–18 % of their re-
current patients) was feasible and offered survival
benefits. Additionally, a few patients, as in our case, ex-
hibited a greater than 5-year survival after surgery. With
respect to the types of surgery, most of the surgeries
were simple resections, such as partial hepatectomy and
mastectomy, and challenging surgeries, like that in our
case, were extremely rare. Surgery for locoregional re-
currence requires extended resection, including adjacent
significant organs and vessels to achieve R0 resection,
and demands a high degree of skill. Therefore, surgical
indication should be carefully determined.
HPD for BTC is one of the most challenging surgeries,
and even today, the surgery is associated with high mor-
bidity; however, the low mortality and survival benefits
of the surgery combined with PV and/or artery resection
has been described [11]. HPD for recurrence of BTC is
Fig. 5 Preoperative schema. The mass involves the duodenum,
pancreatic head, right hepatic artery, and main portal vein. CHA
common hepatic artery, SMV superior mesenteric vein, PV stent
portal vein stent
Fig. 6 Completion photograph of hepatopancreatoduodenectomy.
The white bracket indicates portal vein reconstruction using a
right external iliac vein interposition grafting. The white arrow
indicates arterio-portal anastomosis performed by anastomosing
the common hepatic artery to the portal vein using a left radial
artery interposition grafting
Fig. 7 Macroscopic and histological findings. a Macroscopically, the
mass invades the duodenum, jejunum, and pancreatic head. b
Histological examination reveals a moderately differentiated
adenocarcinoma. PV portal vein, Ph pancreatic head
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rare, and only two cases have been reported previously
[12, 13]. In both of the two reported cases, HPD was
successfully performed without vessel resection in pa-
tients with locoregional recurrence of cholangiocarci-
noma. In our case, intending to a curative resection, it
was assumed that HPD combined with vessel resection
was required because the mass had infiltrated into the
adjacent organs, right hepatic artery, and PV.
Before extended hepatectomy, PVE has been reported
to enlarge the future liver remnant and improve the liver
function [14]. However, PV stenosis, as occurred in our
case, prevents this process. Therefore, PVE with PV stent-
ing was performed. Preoperative PVE with PV stenting
was reported to be effective in a case of severe PV tumor
invasion and stenosis, thus enabling extended hepatec-
tomy to be performed [15].
The patient was scheduled for arterial reconstruction
combining the common hepatic artery and the right
posterior hepatic artery. However, because the patency
of the right posterior hepatic artery was not able to be
confirmed, APS was used. Some reports indicate that
APS is a feasible and safe alternative to the reconstruc-
tion of hepatic arteries [16, 17]. A few complications
after APS, such as bile leakage and liver abscess, have
also been reported. Fortunately, in our case, because
blood flow came from the subphrenic artery to the
remnant liver, there were no serious complications.
Conclusions
By undertaking careful perioperative management, we suc-
cessfully performed a curative resection in a patient with
cholangiocarcinoma recurrence, even though there was
vascular infiltration.
Consent
Written informed consent was obtained from the par-
ents of the patient for publication of this case report and
any accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
journal.
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